Elicio Therapeutics, Inc. (ELTX) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Proceeds from Registered Direct Offering | 15M | FY2026-Q2 |
| Total Enrolled Pancreatic Ductal Adenocarcinoma Patients | 144.00 | FY2025-Q3 |
| Number of Evaluable Patients for Phase 2 AMPLIFY-7P Immunogenicity Assessment | 90.00 | FY2025-Q3 |
Back to ELTX overview · ELTX earnings · ELTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.